Fast Locator 2013-2014: Cambridge - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2013-2014: Cambridge


Untitled Document

Cambridge Major Laboratories, Inc.
W130 N10497 Washington Drive
Germantown, WI 53022

Regions served:
Asia
North America
Europe

Description:
Cambridge Major Laboratories (CML) is a global leader in API development and manufacturing to the pharmaceutical and biotechnology industries.  CML produces pharmaceutical intermediates and API’s from early preclinical development through commercial manufacture.  It is our passion for chemistry that has led CML to have an impeccable reputation for delivering some of the most challenging projects, while meeting the tightest time lines.

CML’s reach is truly global. Operating three facilities in the United State and Europe, CML is organized by five key integrated Centers of Excellence; Process chemistry, API Manufacturing, Analytical Sciences, Solid State Chemistry and Quality Assurance.

Our philosophy revolves around R&D and a deep passion for chemistry.  Nearly 50% of CML scientists hold a Ph.D.  CML is well positioned to deliver on the most challenging and complex chemistry projects.  Strong R&D to support early scale up during preclinical development ensures that your molecule will transition into first-in-human studies as smoothly as possible.  CML has the resources to meet your entire clinical and commercial API needs, and we have developed and scaled-up literally hundreds of projects successfully.

Our passion, expertise, and communication fuel proactive solutions in every project.  When you are looking for a trusted partner to help take your molecule from concept to clinic and beyond, look to CML.

Website
www.c-mlabs.com

Services Provided:

Analytical Services
Chemistry & stability
Particle characterization

Formulation Development & Phase I/II Clinical Trial Materials (CTM)
Active Pharmaceutical Ingredients (API) – small molecule

Commercial Manufacturing
High-potency or high-containment manufacturing (finished drug product)
Active Pharmaceutical Ingredients (API) and advanced intermediates manufacturing – (cGMP, small molecule)

API and advanced intermediates (cGMP, small molecule) manufacturing capabilities
Acetylenic chemistry
Acid chlorides
Acylation
Amidation
Amino Acids and analogs
Asymmetric synthesis or chiral chemistry
Azide chemistry
Biocatalysis
Borane chemistry
Bromine chemistry/bromination
Carbohydrate chemistry
Chemocatalysis
Cryogenics (low-temperature reactions)
Cyanide chemistry
Flourination
Heterocycle chemistry
High-potency/high-containment API manufacturing
Hydrazine chemistry
Lithium chemistry
Nitration
Organometallic chemistry
Phosgenation
Sulfonation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here